Infinant Health, formerly known as Evolve Biosystems, is a privately held company focused on improving infant health through their understanding of infant nutrition and the gut microbiome. Their proprietary research led to the discovery of B. infantis EVC001, a natural bacterial strain essential for infant immune health. Infinant Health aims to reintroduce this beneficial bacteria to infants in developed countries where it has been largely eradicated due to modern medical practices. By leveraging their expertise in metagenomics, bioinformatics, machine learning, and precision medicine, the company develops medical foods, drug pathways, and digital health medical devices to support healthy immune system function and reduce the risk of childhood issues like allergies and type 1 diabetes. Infinant Health believes that early intervention after birth provides the greatest opportunity to impact future health and build a foundation for better overall well-being.